CanBas Co

CanBas Co Tangible Book Value per Share

The Tangible Book Value per Share of CanBas Co (4575.T) as of Oct 19, 2026 is 83.31 JPY. In the previous year, Tangible Book Value per Share was 149.32 JPY — a change of -44.21% (lower).

Tangible Book Value per Share

83.31JPY

YoY

-44.21%

Last updated:

Tangible Book Value per Share of CanBas Co is 2026 83.31 JPY. Tangible Book Value per Share of CanBas Co was 2025 149.32 JPY. It decreases by -44.21% lower compared to the previous year.

The CanBas Co Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2019
33.30 JPY
Jan 1, 2020
12.02 JPY
Jan 1, 2021
22.22 JPY
Jan 1, 2022
12.72 JPY
Jan 1, 2023
98.03 JPY
Jan 1, 2024
118.77 JPY
Jan 1, 2025
149.32 JPY
Jan 1, 2026
83.31 JPY
The CanBas Co Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
83.31JPY-44.21%
149.32JPY+25.72%
118.77JPY+21.15%
98.03JPY+670.74%
12.72JPY-42.76%
22.22JPY+84.87%
12.02JPY-63.90%
33.30JPY+55.54%
21.41JPY-54.48%
47.03JPY-0.17%
47.10JPY-3.67%
48.90JPY+189.10%
16.91JPY-90.13%
171.41JPY-44.16%
306.93JPY-55.48%
689.45JPY-42.75%
1,204.28JPY+32.09%
911.73JPY-10.28%
1,016.14JPY-5.31%
1,073.14JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Tangible Book Value per Share of CanBas Co is 83.31 JPY in 2026.

Tangible Book Value per Share of CanBas Co changed from 149.32 JPY to 83.31 JPY, representing a -44.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share CanBas Co since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CanBas Co

All Key Metrics — CanBas Co